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Abstract
Background: The objective of this article is to present the frequency of cancer in Mexican children who were treated in the
hospitals of the Instituto Mexicano del Seguro Social in Mexico City (IMSS-MC) in the period 1996–2001.
Methods: The Registry of Cancer in Children, started in 1996 in the IMSS-MC, is an on-going, prospective register. The data
from 1996 through 2001 were analyzed and the different types of cancer were grouped according to the International
Classification for Cancer in Children (ICCC). From this analysis, the general and specific frequencies by age and by sex were
obtained for the different groups of neoplasms. Also, the frequency of the stage of the disease that had been diagnosed in cases
of children with solid tumors was obtained.
Results: A total of 1,702 new cases of children with cancer were registered, with the male/female ratio at 1.1/1. Leukemias had
the highest frequency with 784 cases (46.1%) and, of these, acute lymphoblastic leukemias were the most prevalent with 614
cases (78.3%). Thereafter, in descending order of frequency, were tumors of the central nervous system (CNST) with 197 cases
(11.6%), lymphomas with 194 cases (11.4%), germinal cell tumors with 110 cases (6.5%), and bone tumors with 97 cases (5.7%).
The highest frequency of cancer was found in the group of one to four year-olds that had 627 cases (36.8%). In all the age groups,
leukemias were the most frequent. In the present work, the frequency of Hodgkin's disease (~4%) was found to be lower than
that (~10%) in previous studies and the frequency of tumors of the sympathetic nervous system was low (2.3%). Of those cases
of solid tumors for which the stage of the disease had been determined, 66.9% were diagnosed as being Stage III or IV.
Conclusions: The principal cancers in the children treated in the IMSS-MC were leukemias, CNST, and lymphomas, consistent
with those reported by developed countries. A 2.5-fold reduction in the frequency of Hodgkin's disease was found. Of the
children, the stage of whose disease had been determined, two thirds were diagnosed as having advanced stages of the disease.
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Background
The frequency of malignant neoplasms in children has
been found to vary among countries. For example, in chil-
dren in Canada, the United States, and Europe, the three
most common cancers are leukemias, tumors of the cen-
tral nervous system (CNST), and lymphomas [1-3],
whereas in children in Latin America, the order of fre-
quencies is distinct: leukemias are still in first place, with
lymphomas being more common than are CNST [2,4-6].
In other countries such as Nigeria, Malawi, and Egypt,
lymphomas are the principal neoplasias [2].
The percentage of cases of each type of neoplasm in rela-
tion to the total number of cancers is also different. In the
developed countries, the percentages for leukemias range
between 30 and 37%; for CNST, between 18 and 27%;
and for lymphomas, between 7 and 12% [1-3]. In Latin
America, the percentages for leukemias are between 27
and 44%; of lymphomas, between 13 and 22%; and of
CNST, between 10 and 19% [2,4-6]. In African countries,
the percentages of lymphomas range between 30 and 64%
[2]. In Asiatic countries such as Japan and China, the per-
centages of leukemias have been found to be between 30
and 40%; of CNST, between 12 and 20%; and of lympho-
mas, between 10 and 20% [2].
The study of the frequency of cancer in children not only
is of interest to the clinical physician because it helps him/
her to establish the pre-testing probability for a child sus-
pected of having cancer [7], but also is of interest to the
personnel in charge of the planning and programming of
the medical attention for these children, as pertains to the
assignment of human resources (physicians, specialized
nurses, social workers, and others) and to the allotment of
financial resources (centers providing medical attention,
laboratories, imaging facilities, medicines, etc.) that are
necessary for treating the children [8].
In Mexico, there existed data only from retrospective stud-
ies on the epidemiology of cancer in children and those
studies had been carried out prior to 1993 [9,10]. There-
fore, it was necessary to use more recent data, especially
those from prospective studies in which the under-report-
ing of cases was reduced.
The objective of this paper is to present the frequency of
malignant neoplasias in the child population residing in
the area served by the Instituto Mexicano del Seguro
Social (IMSS-MC). The data were obtained from the Reg-
istry of Cancer in Children which was started in 1996 at,
and is maintained by the Hospital de Pediatría del Centro
Médico Nacional "Siglo XXI" of the Instituto Mexicano
del Seguro Social in Mexico City (IMSS-MC).
Methods
Type of study
Observational, descriptive, and prospective hospital
inquiry.
Population studied
The Instituto Mexicano del Seguro Social (IMSS) offers
medical attention to the population of workers and their
families, which comprises 50% of the Mexican popula-
tion [10]. The IMSS divides the population that it attends
into four regions: North, South, East, and West. The IMSS-
Mexico City (IMSS-MC) attends the population of the
Southern region, which includes the populations in vari-
ous states in the country, in addition to that of Mexico
City. With the objective of avoiding a bias in the selection
of the population for the present study, we included for
analysis only cases from those states in which we were
sure that more than 90% of the cases presented had been
registered. This would be true of cases from the states that
are located closest to Mexico City and of the cases in
which the children who developed cancer had to be sent
to Mexico City for treatment. Therefore, the cases analyzed
came from Mexico City and from the following selected
states: State of Mexico, Morelos, Guerrero, and Chiapas. It
should be mentioned that not only the cost of treatment,
but also the cost of transportation to Mexico City is cov-
ered by IMSS. This financial support provided by IMSS to
families helps to ensure that cases of cancer come to the
attention of IMSS-MC and are duly registered.
Newly diagnosed cases of malignant neoplasias in chil-
dren less than 15 years of age treated in the IMSS-MC were
included in this study. In 100% of these cases, the diagno-
sis was confirmed by histological tests and/or by aspira-
tion of the bone marrow.
Participating facilities
The IMSS-MC has two hospitals that provide medical
attention to children with cancer. The Departments of
Hematology and of Pediatric Oncology of both the Hos-
pital de Pediatría of the Centro Médico Nacional "Siglo
XXI" (HP) and the Hospital General del Centro Médico
Nacional "La Raza" (HR) participated in this study. Both
facilities have the infrastructure (competent personnel
and suitable technology) needed for the precise diagnosis
of a cancer.
Study period
Included in this study were the cases attended from 1 Jan-
uary 1996 to 31 December 2001.
Study variables
Prior to carrying out the study, a form for recording the
variables of interest was designed. For this article, the var-
iables analyzed were the following: type of neoplasia, sexBMC Cancer 2004, 4:50 http://www.biomedcentral.com/1471-2407/4/50
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of the patient, age at the time of diagnosis, and the stage
of the cancer for those children with solid tumors.
Procedure
At each hospital, a fulltime nurse was assigned to register
all new cases of cancer. Prior to collecting the data, each
nurse was instructed in procedure necessary for obtaining
all the different variable of the study. The nurse inter-
viewed the parents and reviewed the clinical record of
each child in order to obtain all the necessary
information.
The nurse was also taught how to encode and to deter-
mine the stage of cases of solid tumors. The standardiza-
tion of the coding and determination of the stage of the
solid tumors was done by all personnel (three physicians
and two nurses) concerned with the registry; an excellent
concordance was obtained (unweighted Kappa of 0.85)
[11].
In addition to other duties related to the Registry, each
nurse spent three days a week in the oncology and hema-
tology departments of the hospital (HP or HR), searching
for cases of children who, being suspected of having can-
cer, had been registered in a specific file and boarded at
the hospital. After reviewing the clinical record in each
file, the nurse either included the case in the study (encod-
ing the data if the diagnosis of cancer had been con-
firmed) or eliminated the case if the diagnosis was not
confirmed. If for any reason, the patient was discharged
from the hospital and the diagnosis was undetermined,
the nurse reviewed the clinical record in the clinical
archive of the hospital in order to learn what the final
diagnosis was.
To encode the different cases of cancer, topographical and
morphological coding was used. The second edition of
the "International Classification of Diseases for Oncol-
ogy" (ICD-O-2) was used for the cases collected from
1996 through 1999; the third edition (ICD-O-3), for the
cases collected from 2000 through 2001 [12,13]. For
determining the stage of cases of lymphomas and carcino-
mas, the recommendations of the American Joint Com-
mittee on Cancer (AJCC) and the International Union
Against Cancer (IUAC) were used [14]. The stages for
tumors of the central nervous system (CNST), neuroblas-
toma, retinoblastoma, renal tumors (Wilms' tumor), and
those of the liver, bones, soft tissues, and germinal cells
(GCT) were determined following the recommendations
of the Children's Oncology Group [15].
The Child-Check Program developed by the International
Agency for Research on Cancer (IARC) [16] was used to
evaluate the internal consistency of the individual regis-
tries of cancer and to convert the nomenclature of ICD-O-
2 to the International Classification of Childhood Cancer
(ICCC) [17]. This program made crosses between differ-
ent variables in order to find inconsistencies among the
collected data. The crosses that were made were sex-topog-
raphy, sex-histology, age-tumor type, unlikely combina-
tions of topography-morphology, errors between date of
birth and diagnosis, and duplication of cases. The result
was a list of combinations, although either improbable or
of low probability, that were needed for review in order to
verify data or to correct data by rechecking the records of
the patients. Cases of the ICD-O-3 that were not included
in the Child-Check Program were classified by using other
procedures and the data entered manually.
Statistical analysis
Cases were grouped according to the ICCC [17] that has
established 12 different groups of cancer in children.
From these were calculated the absolute and relative fre-
quencies, both in general and according to sex and to age,
the latter category being divided into four subgroups:
under one year; one to four year-olds; five to nine year-
olds; and ten to 14 year-olds. Due to the fact that the pro-
cedure for the determination of the stage of the disease
was initiated in 1 Jun 1998, such determinations were
made in 658 of the case of solid tumors. Therefore, the fre-
quencies of the diagnostic states were based on this
number of cases of children with solid tumors.
Results
A total of 1,702 cases of malignant neoplasias were ana-
lyzed. Of these, in the order of the most frequently found,
were the following types of tumors: leukemias, 784 cases
(46.1%); CNST, 197 cases (11.6%); lymphomas, 194
cases (11.4%); germinal cell tumors (GCT), 110 cases
(6.5%); and bone tumors (BT), 97 cases (5.7%); and the
remainder of the neoplasias were found in low percent-
ages (Table 1).
Table 1 shows that, in examining the subtypes of the dif-
ferent groups of neoplasias, it was found that, of the
leukemias, the most frequent were the acute lymphoblas-
tic leukemia (n = 614; 78.3%); of the lymphomas, the
non-Hodgkin lymphomas [Burkitt, non Burkitt, and non-
specific together (n = 129; 66.5%)]; of the CNST, the
astrocytomas (n = 97; 49.2%); of the tumors of the sym-
pathetic nervous system (SNST), neuroblastomas and
ganglioneuroblastomas together (n = 36; 92.3%); of the
renal tumors, nephroblastoma [Wilms' tumor (n = 62;
87.3%)]; of hepatic tumors, hepatoblastoma (n = 26;
86.7%); of BT, osteosarcoma (n = 70; 72.2%); of the sar-
comas of the soft tissues, rabdomyosarcoma and embry-
onic sarcoma together (n = 49; 55.1%); of the GCT,
gonadal tumors (n = 80; 72.7%); and of the carcinomas,
adrenocortical, malignant melanoma and skin carcinoma
together (n = 9; 50.1%).BMC Cancer 2004, 4:50 http://www.biomedcentral.com/1471-2407/4/50
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Table 1: Frequency of cancer in children served by the Instituto Mexicano del Seguro Social and treated in hospitals in Mexico City 
(1996–2001).
Diagnostic group Total frequency Frequency by group
n%n%
I. Leukemias 784 46.1 784 100.0
IA. Acute lymphoblastic leukemia 614 36.1 614 78.3
IB. Acute non-lymphoblastic leukemia 146 8.6 146 18.6
CI. Chronic myeloid leukemia 16 1.0 16 2.0
ID. Other specific leukemias 4 0.2 4 0.5
IE. Nonspecific leukemias 4 0.2 4 0.5
II. Lymphomas* 194 11.4 194 100.0
IIA. Hodgkin disease 65 3.8 65 33.5
IIB. Non-Hodgkin lymphoma 104 6.1 104 53.6
IIC. Burkitt lymphoma 21 1.2 21 10.8
IIE. Nonspecific lymphomas 4 0.2 4 2.1
III. Central Nervous System Tumors 197 11.6 197 100.0
IIIA. Ependymoma 29 1.7 29 14.7
IIIB. Astrocytoma 97 5.7 97 49.2
IIIC. Primitive neuroectodermal tumors 52 3.1 52 26.4
IIID. Other gliomas 9 0.5 9 4.6
IIIE. Other specific intracranial and intraspinal neoplasms 9 0.5 9 4.6
IIIF. Other nonspecific intracranial and intraspinal neoplasms 1 0.1 1 0.5
IV. Symphatetic Nervous System Tumors 39 2.3 39 100.0
IVA1. Ganglioneuroblastoma 6 0.3 6 15.4
IVA2. Neuroblastoma 30 1.7 30 76.9
IVB1. Meduloepitelioma 1 0.1 1 2.6
IVB3. Neuroepithelioma 1 0.1 1 2.6
IVB4. Olfactory neuroblastoma 1 0.1 1 2.6
V. Retinoblastoma 73 4.3 73 100.0
V1. Retinoblastoma 46 2.7 46 63.0
V2. Differentiated retinoblastoma 24 1.4 24 32.9
V3. Undifferentiated retinoblastoma 3 0.2 3 4.1
VI. Renal Tumors 71 4.2 71 100.0
VIA1. Nephroblastoma 62 3.6 62 87.3
VIA2. Rabdoid sarcoma 2 0.2 2 2.8
VIA3. Clear-cell sarcoma 6 0.3 6 8.5
VIB. Renal Carcinoma 1 0.1 1 1.4
VII. Hepatic Tumors 30 1.8 30 100.0
VIIA. Hepatoblastoma 26 1.5 26 86.7
VIIB1. Hepatic carcinoma 1 0.1 1 3.3
VIIB2. Hepatic carcinoma undifferentiated 1 0.1 1 3.3
VIIB3. Neuroendocrin e  c a r c i n o m a 10 . 113 . 3
VIIB4. Acinar adenocarcinoma 1 0.1 1 3.3
VIII. Bone Tumors 97 5.7 97 100.0
VIIIA. Osteosarcoma 70 4.1 70 72.2
VIIIB. Chondrosa r c o m a 40 . 244 . 1
VIIIC. Ewing sarcoma 18 1.1 18 18.6
VIIID. Other specific malignant tumors 3 0.2 3 3.1
VIIIE. Unspecified maligna n t  b o n e  t u m o r s 20 . 222 . 1
IX. Soft-Tissue Sarcomas 89 5.2 89 100.0
IXA. Rhabdomyosarcoma and embryonal sarcoma 49 2.9 49 55.1
IXB. Fibrosarcoma, neurofibrosarcoma and others fibromatous neoplasms 21 1.2 21 23.6
IXD. Other specific soft tissue sarcomas 17 1.0 17 19.1
IXE. Unspecified soft tissue sarcomas 2 0.2 2 2.2
X. Germ Cell Tumors 110 6.5 110 100.0
XA. Intracranial and intraspinal germ cell tumors 15 0.9 15 13.6
XB. Other and unspecified non-gonadal germ cell tumors 13 0.8 13 11.8
XC. Gonadal germ cell tumors 80 4.7 80 72.7
XD. Gonadal carcinomas 2 0.2 2 1.8
n
p
o
r
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The percentages of the different neoplasias showed varia-
tions according to sex and age group. These findings mod-
ified the pattern of presentation and made it different
from the overall pattern. In males, over 70% of the cases
consisted of the following types of tumors: leukemias (n
= 412; 46.6%); lymphomas (n = 138; 15.6%); and CNST
(n = 84; 9.5%). In females, 73.6% of the cases consisted of
leukemias (n = 372; 45.5%); CNST (n = 113; 13.8%); GCT
(n = 61; 7.5%); and lymphomas (n = 56; 6.8%). Overall,
the ratio of males to females was 1.1; however, this ratio
varied for the different groups of neoplasias, most notably
a high of 2.5 for lymphomas and a low of 0.8 for both
hepatic tumors, BT and GCT (Table 2).
Table 2 shows that, for all age groups, leukemias had the
highest frequency, ranging between 27.9 to 50.5%. In sec-
ond and third place for the different age groups were the
following types of tumors: under one year of age, retino-
blastoma (n = 15; 17.4%) and GCT (n = 13; 15.1%); 1–4
year-olds, CNST (n = 69; 11.0%) and retinoblastoma (n =
56; 8.9%); 5–9 year-olds, lymphomas (n = 79; 16.2%)
and CNST (n = 59; 12.1%); and 10–14 year-olds, lympho-
mas (n = 66; 13.2%) and BT (n = 65; 12.9%).
With respect to the neoplasias in patients from other
states in the Mexican Republic, leukemias were also found
to have the highest frequency, followed by lymphomas
and/or CNST, with discrete variations in the frequencies
as mentioned above. It should be noted that in one state
(Chiapas), although retinoblastoma was only the fourth
most frequent there, its frequency (8.9%) was one of the
highest (Table 3).
In regard to the spread of the disease at the time of diag-
nosis for those children the stage of whose solid tumors
had been determined, 89 (13.5%) were Stage I; 129
(19.6%), Stage II; 242 (36.8%), Stage III; and 198
(30.1%), Stage IV or higher.
Discussion
This is the first report of data, covering the six year period
from 1996–2001, taken from the on-going Registry of
Cancer in Children that was started in 1996 in Mexico
City by the Instituto Mexicano del Seguro Social (IMSS-
MC). The strategy of having placed a nurse in each of the
two hospitals involved with the Registry of Children with
Cancer resulted in the great majority (more than 90%) of
the new cases that were treated by the two hospitals being
identified and duly registered. We therefore concluded
that this Registry of Cancer in Children was one of the
most complete of its kind undertaken in Mexico City.
Having access to the clinical records of the patients served
to improve the quality of the data that was registered
because, since cases were registered as soon as they were
diagnosed, few cases were overlooked.
The quality of the data was also enhanced by the use of the
Child-Check Program, with which the possible errors, not
only of registry but also of capture, were reviewed and
were eliminated upon rechecking the respective clinical
record in the hospital files. As mentioned in Methods, in
100% of the cases, the histopathology reports for children
with solid tumors, or the reports on the aspirated bone
marrow for children with leukemia, were obtained. There-
fore, the data that was obtained for the children with can-
cer who were residents in the area covered by IMSS-MC
and treated in Mexico City were the most precise that have
been gathered to date in Mexico.
The frequency of a disease in a population is a method of
obtaining the pre-test probability that a patient has before
a diagnostic test is performed [7]. It is important that this
value be known, because there is a direct correlation with
the positive predictive value of the test. This, in turn, is the
probability that an individual whose test result was posi-
tive has of having the suspected disease [7]. That is, in the
case of the children who were attended in the tertiary
health care hospitals in IMSS-MC, the pre-test probability
for a child whose parents sought medical attention (with-
out taking into account his/her symptomatology) is a
43.4% chance of having some form of leukemia, an
11.1% chance of lymphoma, or a 12.6% chance of CNST.
This probability increases or decreases depending on the
XI. Carcinomas 18 1.1 18 100.0
XIA. Adrenocortical carcinoma 3 0.2 3 16.7
XIB. Thyroid carcinoma 1 0.1 1 5.5
XIC. Nasopharyngeal carcinoma 1 0.1 1 5.5
XID. Malignant melanoma 3 0.2 3 16.7
XIE. Skin carcinoma 3 0.2 3 16.7
XIF. Other and unspecified carcinomas 7 0.4 7 38.9
Total 1702 100.0 1702 100.0
* 40 cases of Histiocytosis were not included Note: Numbers in circles indicate the five highest frequencies, in descending order
Table 1: Frequency of cancer in children served by the Instituto Mexicano del Seguro Social and treated in hospitals in Mexico City 
(1996–2001). (Continued)BMC Cancer 2004, 4:50 http://www.biomedcentral.com/1471-2407/4/50
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symptomatology that the child presents, on the test
requested, and on the result (positive or negative) of said
test. Knowing the frequency of diseases in general and, in
this case, the frequency of the different types of cancer that
Mexican children present is therefore an important aid in
diagnosis. The same can be said for the frequency of can-
cer by age and by sex.
As has been mentioned, knowing the frequency of dis-
eases serves in the estimation of administrative needs, not
only with respect to personnel but also to the equipment
and supplies necessary for diagnosis and treatment, and
for providing medical attention in general and in particu-
lar for children with cancer [8]. Given that, from the data,
46.1% of these children develop leukemia, appropriate
provision has to be made for their treatment, as well as for
the children with other forms of cancer.
A more clinical aspect, particular to children with cancer,
that indicated the spread of their disease was the stage of
the disease at the time of diagnosis. It was established that
66.9% were in stages III or IV, a finding that generally
means the prognosis for the patient is not good. This
datum was consistent with, and more precise than the
result of the previously reported retrospective study, in
which it was found that 56.4% had been diagnosed as
having an advanced stage (III or IV) of the disease [10].
This fact indicates that, for Mexican children that develop
a cancer, programs for integrated medical attention must
be designed such that early diagnosis is a priority.
Although the early diagnosis of cancer in children as a fac-
tor in a good prognosis is controversial [18], it is probable
that such a program would have a great impact in Mexico.
For this reason, as has been pointed out in prior studies
[19], the influence of various factors such as the patient's
family (educational level, socio-economic status, etc.), the
type of cancer, the age of the child, the health system, and
the physicians that care for the child on intake must be
taken into account.
Although the results obtained for the different groups of
cancer in Mexican children in this study showed general
agreement with data previously reported, there were some
differences. Consistent with data obtained in other studies
[9,10], it was found that leukemia, CNST, and lymphoma
were the principal neoplasias and that Mexican children
have one of the highest percentages of leukemias in the
world (46.1% vs. 27–44%) [2,20,21].
In contrast to previous studies in Mexico, the frequency of
Hodgkin's disease was notably lower, thus reducing the
overall frequency of lymphoma to slightly lower than that
of CNST and putting it in the range reported for developed
countries (11.4% vs. 7–12%) [2]. We consider this reduc-
tion in the frequency of Hodgkin's disease a noteworthy
and probably real effect, not just an artifact of the quality
of the registry.
Table 2: Frequency of cancer, according to sex and to age group, in children served by the Instituto Mexicano del Seguro Social and 
treated in hospitals in Mexico City (1996–2001).
Diagnostic group Age group (years) Sex
< 1 1–4 5–9 10–14 Male Female Ratio
N%n%n%n%n%n% M / F
I. Leukemias 24 27.9 301 48.0 246 50.5 213 42.4 412 46.6 372 45.5 1.1
II. Lymphomas* 0 0.0 49 7.8 79 16.2 66 13.2 138 15.6 56 6.8 2.5
H o d g k i n  d i s e a s e 0 0 . 0 7 1 . 12 65 . 33 26 . 44 34 . 92 22 . 71 . 9
Non-Hodgkin 
lymphoma
0 0.0 42 6.7 53 10.9 34 6.8 95 10.7 34 4.1 2.8
III. CNST 6 7.0 69 11.0 59 12.1 63 12.5 84 9.5 113 13.8 0.7
IV. SNST 9 10.5 21 3.3 5 1.0 4 0.8 20 2.3 19 2.3 1.1
V. Retinoblastoma 15 17.4 56 8.9 1 0.2 1 0.2 34 3.8 39 4.8 0.9
VI. Renal Tumors 7 8.1 44 7.0 15 3.1 5 1.0 39 4.4 32 3.9 1.2
VII. Hepatic Tumors 7 8.1 11 1.8 7 1.4 5 1.0 13 1.5 17 2.1 0.8
V I I I .  B o n e  T u m o r s00 . 061 . 0 2 6 5 . 3 6 5 12.9 4 34 . 95 46 . 60 . 8
IX. Soft Tissue 
Sarcomas
5 5 . 82 94 . 62 34 . 73 26 . 44 34 . 94 65 . 60 . 9
X. Germ Cell 
Tumors
13 15.1 3 86 . 11 93 . 94 08 . 04 95 . 56 1 7.5 0.8
XI. Carcinomas 0 0.0 3 0.5 7 1.4 8 1.6 9 1.0 9 1.1 1.0
Total 86 100 627 100 487 100 502 100 884 100 818 100 1.1
* 40 cases of Histiocytosis were not included M: male; F: female Numbers in circles indicate the three highest frequencies, in descending order 
CNST: central nervous system tumors SNST: sympathetic nervous system tumors
n n n n n n
o o o
o p p o
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Table 3: Frequency of cancer in children* of different states of the mexican republic served by the Instituto Mexicano del Seguro Social 
and treated in hospitals in Mexico City (1996–2001).
Diagnostic group Chiapas Mexico City Guerrero State of Mexico Morelos
n%n%n%n%n%
I. Leukemias 46 37.4 280 43.5 33 31.7 377 51.5 48 48.0
II. Lymphomas** 13 10.6 83 12.9 20 19.2 67 9.2 11 11.0
Hodgkin disease 4 3.3 21 3.3 6 5.8 32 4.4 2 2.0
Non-Hodgkin lymphoma 9 7.3 62 9.6 14 13.5 35 4.8 9 9.0
III. CNST 18 14.6 85 13.2 19 18.3 67
9.2
8 8.0
IV. SNST 1 0.8 17 2.6 7
6.7
1 2 1 . 622 . 0
V. Retinoblastoma 11 8.9 2 2 3 . 454 . 8 3 1 4 . 244 . 0
VI. Renal tumors 4 3.3 26 4.0 5 4.8 30 4.1 6 6.0
VII. Hepatic tumors 3 2.4 18 2.8 0 0.0 8 1.1 1 1.0
VIII. Bone tumors 9 7.3 31 4.8 7 6.7 43 5.9 7 7.0
IX. Soft tissue sarcomas 8 6.5 35 5.4 43 . 8 3 6 4 . 96 6.0
X. Germ cell tumors 6 4.9 42 6.5 21 . 9 5 5 7.5 55 . 0
XI. Carcinomas 4 3.3 4 0.6 2 1.9 6 0.8 2 2.0
Total 123 100 643 100 104 100 732 100 100 100
Note: Numbers in circles indicate the five highest frequencies in descending order *Children 0–14 years **40 cases of histiocytosis were not 
included CNST: central nervous system tumors SNST: sympathetic nervous system tumor
Table 4: Comparison of the frequency of cancer in children* in Mexico City and in four selected countries
Diagnostic 
Group
Mexico City 
1980–19919/
Mexico City 
1992–199310/
Mexico City 
1996–2001
USA-SEER 
White 
1983–19922/
German Fed-
eral Republic 
1985–19902/
France 
1983–19923/
Cuba 
1986–19905/
n%n% n%n % n % n%n%
I. Leukemias 1706 34.9 78 39.2 784 46.1 1757 30.7 2422 34.4 746 29.4 454 30.7
II. Lymphomas** 888 18.2 34 17.6 194 11.4 616 10.7 781 11.1 310 12.2 271 18.3
Hodgkin disease 524 10.7 18 9.0 65 3.8 259 4.5 279 4.0 103 4.1 84 5.7
Non-Hodgkin 
lymphoma
364 7.5 16 8.6 129 7.6 357 6.2 502 7.1 207 8.1 187 12.6
III. CNST 496 10.2 25 12.6 197 11.6 1222 21.4 1392 19.8 538 21.2 223 15.1
IV. SNST 133 2.7 6 3.0 39 2.3 469 8.2 552 7.8 244 9.6 104 7.0
V. Retinoblastoma 420 8.6 5 2.5 73 4.3 172 3.0 208 2.9 61 2.4 40 2.7
VI. Renal Tumors 279 5.7 9 4.5 71 4.2 366 6.4 464 6.6 152 5.9 69 4.7
VII. Hepatic 
Tumors
70 1.4 1 0.5 30 1.8 83 1.5 82 1.2 23 0.9 21 1.4
VIII. Bone Tumors 321 6.6 94 . 59 7 5.7 267 4.7 359 5.1 129 5.1 87 5.9
IX. Soft Tissue 
Sarcomas
238 4.9 10 5.0 89 5.2 387 6.8 492 7.0 154 6.1 91 6.2
X. Germ Cell 
Tumors
256 5.2 17 8.6 110 6.5 165 2.9 222 3.2 71 2.8 34 2.3
XI. Carcinomas 55 1.1 3 1.5 18 1.1 193 3.4 55 0.8 108 4.3 55 3.7
XII. Nonspecific 18 0.4 0 0 0 0.0 21 0.4 7 0.1 2 0.1 29 2.0
Total 4880 100 198 100 1702 100 5718 100 7036 100 2538 100 1478 100
Note: Numbers in circles indicate the five highest frequencies, in descending order *Children 0–14 years **40 cases of histiocytosis were not 
included CNST: central nervous system tumors SNST: sympathetic nervous system tumor References 2,3,5,9,10.
n n n n n
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The previous studies, being retrospective, had a greater
tendency to under-register the number of cases and there-
fore result in an lower frequency than the actual value; yet,
here, with a more accurate study, the frequency obtained
was lower still (10% a 3.8%) (Table 4) [9,10]. However,
we consider it necessary to obtain the incidence rates to
confirm this and will do so for a forthcoming study in
which we will present exclusively the incidence of cancer
in children who are residents of Mexico City. It should be
mentioned that the same phenomenon (reduction in the
HD) was shown by Linet et al. [22] in their study of chil-
dren in the U.S. during the period 1974 to 1995. There has
been no explanation of this phenomenon because no pro-
gram attempting to reduce HD in Mexico or in other parts
of the world has been established. However, should an
infectious agent be one of the causes in the development
of HD, it is possible that the indiscriminant use of antivi-
ral and/or antibiotics in Mexico may play a role. Perhaps
future studies will be able to explain the phenomenon.
In this and the two prior studies in Mexico, the frequency
of CNST was found to be less than that in developed coun-
tries (18–27%). However, the lowered frequency of lym-
phomas found in the present study changed the
hierarchical pattern of tumors, with CNST now having
just edged out lymphomas for second place. We do not
consider that this population has, strictly speaking, the
pattern of U.S.-Canada-Europe, nor that of Latin America.
We can say that the pattern of neoplasias in Mexican chil-
dren was found to be a phenomenon in transition. It was
interesting that the pattern of presentation found in chil-
dren in Mexico City was different to that of the children
that live in the northern part of the country (data not
shown). The pattern in children from the north was
similar to that of children in the U.S. and Canada, in that
the principal neoplasias were leukemias, CNST, and lym-
phomas and had very similar frequencies [23,24]. This
finding suggested the possibility that factors which cause
cancer in children in the north of Mexico may be different
to those causing cancer in children in Mexico City.
Data for children under one year of age showed that,
whereas neuroblastoma was the principal tumor for this
age group in developed countries [1,3], in our study it was
leukemias (27.9%), with the frequency of neuroblastoma
being much lower than in developed countries (10.5 vs.
27.4). This finding is one that should be followed up
because there are two factors that would have affect the
reported number of cases and, hence the frequency:
Because Mexico does not have the screening programs for
detecting children with neuroblastoma that other coun-
tries do [25], it was probable that cases of this disease were
not being diagnosed. Also, it is known that some of these
tumors do regress spontaneously [26].
Another interesting aspect of the present study was that
one of the highest frequencies of GCT (6.5%) in the world
was found, a frequency similar to that for some Asiatic
countries, such as Japan and Singapore (6.8%) [2]. We do
not have an explanation of this finding, but studies
directed toward establishing the causes of this high fre-
quency should be carried out.
Finally, it should be mentioned that one state of the Mex-
ican Republic, Chiapas, was found to have one of the
highest frequencies of retinoblastoma (8.9%), a frequency
very similar to that of countries of Africa (Zimbabwe,
9.6%) and in India (Madras; 9.4%) [2]. Chiapas is one of
the poorest states in Mexico and, as has been suggested, it
is possible that the state of nutrition may play a role in the
development of this tumor [27]. However, as for Hodg-
kin's Disease, it will be necessary to calculate the incidence
rates to make this observation more precise.
Conclusions
It may be concluded that, in the children residing in Mex-
ico City that were included in this study, the principal
neoplasias were leukemias, CNST, and lymphomas, find-
ings that were consistent with previously published data.
It was found that, in comparison to previous studies in
Mexico City, there was a reduction in the frequency of
lymphomas and especially of Hodgkin's disease, and that,
of the children with solid tumors, two thirds were diag-
nosed as having advanced stages (III-IV) of the disease.
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